Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 50 million lambs have been treated and over 60% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics.
He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Matthew is Head of Cardiothoracic Surgery at Strathfield Private Hospital and the Royal Prince Alfred Hospital. He is also a Fellow of the Royal Australasian College of Surgeons.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr. Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Humans

Unmet human pain and wound care need

At present there is no commercially available product for humans that can be sprayed onto wounds in emergency situations to promptly alleviate pain, minimise bleeding, provide antisepsis and create a protective barrier.

Demonstrated commercial success

We have demonstrated the commercial success of our lead product, Tri-Solfen®, for animals. Data from these animal studies suggests that a similar formulation may be equally safe and effective for use on humans. A multi-function topical formulation, such as Tri-Solfen®, has the potential to revolutionise the acute management of open wounds in humans, to alleviate suffering, to reduce the risk of blood loss and infection and improve recovery, in the same manner that it has done in animals.

We are therefore undertaking research and development to optimise the formulation and packaging of Tri-Solfen® for human use, and to investigate regulatory options for bringing the product to market.

We are now developing our technology to prevent pain and minimise suffering associated with wounds in humans

Chronic wound care

Treating chronic wounds for venous leg ulcers, diabetic foot ulcers and pressure ulcers

Chronic wounds affect millions of people globally, which is expected to rise significantly due to the increasing proportion of elderly patients living longer. There are three main types of chronic wounds; venous leg ulcers, diabetic foot ulcers and pressure ulcers. We are initially focused on the development of our technology for the treatment of venous leg ulcers, which represent 80% of all chronic ulcers.

Cleansing chronic wounds of local barriers, such as dead tissue, is known as debridement and is an essential process to facilitate efficient healing. It has been shown that faster and more complete healing is achieved with more frequent debridement.

However, debridement of chronic wounds is not well tolerated and patients will often ask clinicians to stop before the procedure is completed, or avoid the procedure, because of the pain and discomfort. This pain also extends beyond completion of the procedure.

Patients with venous leg ulcers report pain to be the worst aspect of having an ulcer. Chronic pain is highly complex, may extend over months or years, and has enormous implications for a patient’s quality of life, causing decreased activities of daily living, sleep disturbance, reduced mobility and social withdrawal.

It has been shown that when patients with venous leg ulcers feel an ease or absence of pain they interpret it as a positive sign of wound healing, which can make them feel hopeful and optimistic.

Supported by our trial data from our approved animal product (Tri-Solfen®), we have agreed a clinical development protocol for human use of our technology in venous leg ulcers.

1 in 500 people suffering

Venous leg ulcers are estimated to affect around 1 in 500 people in the UK, although they become much more common with age. It's estimated that around 1 in 50 people over the age of 80 has one.

Up to 10% of diabetics

422 million adults have diabetes. Up to 10% of them will develop a diabetic foot ulcer at some point.

Future opportunities

Future near-term opportunities we have identified for our technology include the treatment of traumatic wounds caused by surgical procedures and mass trauma situations such as accidents, military conflict and natural disasters.

Future opportunities in humans include:

  • Chronic wound care
    • Diabetic leg ulcers
  • Immediate wound treatment
    • Medical clinics
    • Defence forces
    • Emergency services
    • Natural disaster situations
  • Post-surgery wound care
    • Post-surgical treatments
  • Over-the-counter first aid treatments